Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | OGG1 | O15527 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.41 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422333 | 0.87 | ALDH1A1 (0.73) | ALDH1A1KDM4ELMNAOGG1MEN1 | |
| SCHEMBL15426830 | 0.82 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNAOGG1MEN1 | |
| SCHEMBL4413701 | 0.82 | ALDH1A1 (0.67) | ALDH1A1KDM4ELMNAOGG1MEN1 | |
| SCHEMBL13946509 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL1303739 | 0.79 | ALDH1A1 (0.68) | ALDH1A1KDM4ELMNAOGG1MEN1 | |
| SCHEMBL1713424 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL11872758 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAOGG1MEN1 | |
| SCHEMBL2835832 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAOGG1MEN1 | |
| SCHEMBL5434584 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAMEN1KMT2A | |
| SCHEMBL11547674 | 0.79 | ALDH1A1 (0.63) | ALDH1A1KDM4ELMNAOGG1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | ALDH1A1 3574/4885KDM4E 508/4885LMNA 4714/4885 |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | ALDH1A1 1981/4885KDM4E 1286/4885LMNA 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.